VENCLYXTO in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
VENCLYXTO IS THE FIRST APPROVED BCL‑2
INHIBITOR FOR THE TREATMENT OF AML1
VENCLYXTO IS THE FIRST APPROVED BCL‑2
INHIBITOR FOR THE TREATMENT OF AML1
VENCLYXTO IS THE FIRST APPROVED BCL‑2 INHIBITOR FOR THE TREATMENT OF AML1
Need to revisit or download past content?
ACCESS AVAILABLE RESOURCES
from recent hematology-oncology congresses right here
2022
American Society of Hematology (ASH)
Note to affiliates: local sites should link to relevant events
2022
American Society of Clinical Oncology (ASCO)
Note to affiliates: local sites should link to relevant events
2022
European Hematology Association (EHA)
Note to affiliates: local sites should link to relevant events
2022
Society of Hematologic Oncology (SOHO)
Note to affiliates: local sites should link to relevant events
International Symposium on Acute Leukemias (ISAL) XVIII Meeting
March 19-22, 2023
Munich, Germany & online
Note to affiliates: local sites should link to relevant events
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2-6, 2023
Chicago, Illinois, United States & online
Note to affiliates: local sites should link to relevant events
European Hematology Association (EHA) Annual Meeting
June 8-11, 2023
Frankfurt, Germany & online
Note to affiliates: local sites should link to relevant events
European School of Haematology (ESH) Meeting
6th International Conference: Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
October 29-31, 2023
Estoril, Portugal
Note to affiliates: local sites should link to relevant events
American Society of Hematology (ASH)
December 9-12, 2023
San Diego, California, United States (and online)
Note to affiliates: local sites should link to relevant events
Note to affiliates: Please use your locally approved pieces for HCP TOOLS.
RIGHT START DIALOGUE TOOL
An interactive PDF you can use with patients and caregivers. Designed to support meaningful conversations about AML and VENCLYXTO. This tool covers:
- What is an AML diagnosis?
- Treatment initiation with VENCLYXTO
- How to take VENCLYXTO prescribed
DOSING GUIDE—STARTING PATIENTS ON VENCLYXTO
A booklet that you can share with your patients to help them understand what to expect when taking VENCLYXTO. This dosing guide includes:
- How to take VENCLYXTO
- Dose modifications
- Tumour lysis syndrome prevention
- Key safety and lifestyle considerations while on VENCLYXTO
AML THERAPY OPTIMIZATION TOOL KIT
A tool kit, for your use only, with key information to help you successfully initiate and manage your patients' AML treatment with VENCLYXTO. This kit includes:
- Considerations before starting VENCLYXTO
- How to start VENCLYXTO/the AML ramp-up dosing schedule
- Key safety information and dosing/schedule modifications
- Drug-drug interactions and VENCLYXTO dose modifications
I want to know how VENCLYXTO's MoA works
I want to review the adverse events profile
Reference: 1. VENCLYXTO Summary of Product Characteristics. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG. December 2022.
ALL-VNCAML-220066 October 2023